The effect of timing of teriparatide treatment on the circadian rhythm of bone turnover in postmenopausal osteoporosis

被引:38
|
作者
Luchavova, Maria [1 ,3 ]
Zikan, Vit [1 ,3 ]
Michalska, Dana [1 ,3 ]
Raska, Ivan, Jr. [1 ,3 ]
Kubena, Ales A. [2 ]
Stepan, Jan J. [4 ]
机构
[1] Gen Univ Hosp Prague, CZ-12808 Prague, Czech Republic
[2] Acad Sci Czech Republic, Inst Informat Theory & Automat, CZ-18208 Prague, Czech Republic
[3] Charles Univ Prague, Dept Internal Med 3, Dept Endocrinol & Metab, Fac Med 1, CZ-12808 Prague, Czech Republic
[4] Charles Univ Prague, Inst Rheumatol, Fac Med 1, CZ-12808 Prague, Czech Republic
关键词
INTACT PARATHYROID-HORMONE; SERUM CORTISOL; DIURNAL RHYTHM; GROWTH-HORMONE; IN-VIVO; RESORPTION; OSTEOPROTEGERIN; CALCIUM; ABNORMALITIES; OSTEOCALCIN;
D O I
10.1530/EJE-10-1108
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: We hypothesized that with the administration of teriparatide (TPTD) treatment at different times, we would be able to modify the physiological circadian rhythm of bone turnover. Methods: The concentration of serum C-terminal telopeptide of collagen type I (beta CTX), serum N-terminal propeptide of procollagen type I (P1NP), serum ionized calcium (iCa), and plasma PTH were measured every 3 h over a 24 h period in 14 postmenopausal osteoporotic women (aged 72.4 +/- 9.3 years) treated with 20 mu g TPTD for long term, given at different times of the day. General linear model-repeated measurements (GLM RM) were performed to analyze the circadian rhythms as well as intergroup comparisons. Results: GLM-RM for both related groups showed a significant influence of time of day on all measured variables except P1NP. The analysis for each group separately provided a powerful model for beta CTX (P < 0.001, eta(2) = 0.496), serum iCa (P < 0.001, eta(2) = 0.423), plasma PTH (P < 0.001, eta(2) = 0.283), and serum PINP (P < 0.001, eta(2) = 0.248). While the evening TPTD treatment showed a marked circadian rhythm for serum beta CTX, the morning TPTD treatment rather suggested circasemidian rhythm. The P1NP rhythm followed a much smaller amplitude of the rhythm than beta CTX. Changes in serum iCa were positively related to changes in serum beta CTX (P < 0.001) and negatively related to changes in PTH (P < 0.001). Conclusion: Timing of TPTD administration may significantly change the 24 h variation in bone turnover markers as well as calcium-parathyroid axis in postmenopausal osteoporotic women.
引用
收藏
页码:643 / 648
页数:6
相关论文
共 50 条
  • [31] The effect of raloxifene on bone marrow adipose tissue and bone turnover in postmenopausal women with osteoporosis
    Beekman, Kerensa M.
    Veldhuis-Vlug, Annegreet G.
    den Heijer, Martin
    Maas, Mario
    Oleksik, Ania M.
    Tanck, Michael W.
    Ott, Susan M.
    van't Hof, Rob J.
    Lips, Paul
    Bisschop, Peter H.
    Bravenboer, Nathalie
    BONE, 2019, 118 : 62 - 68
  • [32] Uncoupling bone turnover with strontium ranelate, a promising agent for the treatment of postmenopausal osteoporosis
    Christiansen, C
    Tankó, LB
    OSTEOPOROSIS INTERNATIONAL, 2004, 15 : S98 - S98
  • [33] EFFECTS OF DIMETHIL PAMIDRONATE TREATMENT ON BIOCHEMICAL MARKERS OF BONE TURNOVER IN POSTMENOPAUSAL OSTEOPOROSIS
    ZANCHETTA, JR
    BOGADO, CE
    JOURNAL OF BONE AND MINERAL RESEARCH, 1992, 7 : S196 - S196
  • [34] Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women
    Shiraki, M.
    Sugimoto, T.
    Nakamura, T.
    OSTEOPOROSIS INTERNATIONAL, 2013, 24 (01) : 219 - 226
  • [35] Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women
    M. Shiraki
    T. Sugimoto
    T. Nakamura
    Osteoporosis International, 2013, 24 : 219 - 226
  • [36] BIOCHEMICAL MARKERS OF BONE TURNOVER IN TREATMENT WITH TERIPARATIDE AND TERIPARATIDE IN COMBINATION WITH DENOSUMAB
    Blazquez, J. A.
    Navarro-Martinez, A.
    Torres, J.
    Navarro-Casado, L.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 35 : S311 - S311
  • [37] THE USE OF TERIPARATIDE IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - EXPERIENCE OF USING BONE MARKERS AND BONE MINERAL DENSITY TO MONITOR RESPONSE
    Hollick, Rosemary J.
    Reid, David M.
    Black, Alison J.
    OSTEOPOROSIS INTERNATIONAL, 2012, 23 : S574 - S575
  • [38] The use of teriparatide in the treatment of postmenopausal osteoporosis: experience of using bone markers and bone mineral density to monitor response
    Hollick, R. J.
    Reid, D. M.
    Black, A. J.
    SCOTTISH MEDICAL JOURNAL, 2013, 58 (04) : E33 - E34
  • [39] CHANGES IN BONE TURNOVER MARKERS CAN PREDICT THE RESPONSE IN BONE MINERAL DENSITY DURING TERIPARATIDE TREATMENT IN OSTEOPOROSIS
    Moro-Alvarez, M.
    Cogolludo-Perez, F.
    Andrade, M.
    de la Piedra, C.
    Diaz-Curiel, M.
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 77 - 77
  • [40] Factors associated with bone response to teriparatide in young postmenopausal women with osteoporosis
    Anna, Gosset
    Anne-Lise, Farcy
    Clemence, Dufond
    Jean-Michel, Pouilles
    Florence, Tremollieres
    JOURNAL OF BONE AND MINERAL METABOLISM, 2023, 41 (2) : 278 - 285